

## PROXY FORM

in accordance with Chapter 7 Section 54 (a) of the Swedish Companies Act

I hereby appoint the proxy stated below, or whomever he or she may appoint, to vote on my behalf for all my shares in Cinclus Pharma Holding AB (publ), Reg. No. 559136-8765, at the Annual General Meeting of Cinclus Pharma Holding AB (publ) on 22 May 2025.

### Proxy

Name of the proxy	Personal identity number/Date of birth
Address	
Postal code and city	Telephone number

### Signature by the shareholder

Name of the shareholder	Personal identity number/Date of birth/Registration number
Place and date	Telephone number
Signature*	

\*If signing for a company, a clarification of signature shall be included above and an up to date certificate of registration (or the equivalent) shall be enclosed to the completed proxy form.

Please note that a shareholder shall give the company notice of attendance – as set out in the notice convening the meeting – even if the shareholder intends to exercise his or her voting rights through a proxy.

The completed proxy form (with any enclosures) should be sent to Cinclus Pharma, by post to Cinclus Pharma Holding AB (publ), Klarabergsviadukten 70, Elevator K, Floor 3, SE-111 64 Stockholm, Sweden or via e-mail to [cincluspharma.generalmeetings@vinge.se](mailto:cincluspharma.generalmeetings@vinge.se), so that it has been received by Cinclus Pharma at the latest on 21 May 2025. For the avoidance of doubt, if the shareholder does *not* intend to exercise his or her voting rights through a proxy, the proxy form does not have to be submitted.

#### ***Processing of personal data***

For information on how your personal data is processed, please refer to the Integrity Policy available on the Euroclear website; <https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf>.